Merck & Co Inc Stock in Q2 2019 Driven by Institutional Investors

Merck & Co., Inc. (NYSE:MRK) Logo

Sentiment for Merck & Co Inc (NYSE:MRK)

Merck & Co Inc (NYSE:MRK) institutional sentiment increased to 1.09 in Q2 2019. Its up 0.27, from 0.82 in 2019Q1. The ratio is positive, as 715 investment managers increased or started new positions, while 658 trimmed and sold positions in Merck & Co Inc. The investment managers in our partner’s database reported: 1.84 billion shares, down from 1.85 billion shares in 2019Q1. Also, the number of investment managers holding Merck & Co Inc in their top 10 positions decreased from 148 to 125 for a decrease of 23. Sold All: 54 Reduced: 604 Increased: 574 New Position: 141.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $211.40 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 23.15 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

The stock decreased 0.24% or $0.19 during the last trading session, reaching $82.57. About 4.70 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 28.05% since September 13, 2018 and is uptrending. It has outperformed by 28.05% the S&P500.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on October, 24. They expect $1.25 earnings per share, up 5.04 % or $0.06 from last year’s $1.19 per share. MRK’s profit will be $3.20 billion for 16.51 P/E if the $1.25 EPS becomes a reality. After $1.30 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts -3.85 % negative EPS growth.

Srb Corp holds 14.42% of its portfolio in Merck & Co., Inc. for 1.84 million shares. Terril Brothers Inc. owns 224,533 shares or 6% of their US portfolio. Moreover, Foundation Resource Management Inc has 5.67% invested in the company for 330,729 shares. The United Kingdom-based Parus Finance (Uk) Ltd has invested 5.45% in the stock. Wilkins Investment Counsel Inc, a Massachusetts-based fund reported 207,693 shares.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Ratings analysis reveals 100% of Merck & Company’s analysts are positive. Out of 4 Wall Street analysts rating Merck & Company, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8400 while the high is $10300. The stock’s average target of $93.60 is 13.36% above today’s ($82.57) share price. MRK was included in 13 notes of analysts from March 22, 2019. Cantor Fitzgerald maintained it with “Buy” rating and $95 target in Friday, March 22 report. Bank of America maintained the stock with “Buy” rating in Friday, June 21 report. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Friday, June 21 by Morgan Stanley.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “Merck (MRK) Pooled Analysis Continues to Show its KEYTRUDA in Combination with Chemotherapy Improved OS for Patients with Advanced NSCLC –” on September 10, 2019, also with their article: “Gilead Tops List of Most Innovative Drug Companies – Yahoo Finance” published on September 12, 2019, published: “Income Investors Should Know That Merck & Co., Inc. (NYSE:MRK) Goes Ex-Dividend Soon – Yahoo Finance” on September 09, 2019. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: and their article: “Merck & Co., Inc.’s (MRK) Management Presents at Morgan Stanley 17th Annual Global Healthcare Conference 2019 – Transcript – Seeking Alpha” published on September 09, 2019 as well as‘s news article titled: “Can Merck & Co., Inc.’s (NYSE:MRK) ROE Continue To Surpass The Industry Average? – Yahoo Finance” with publication date: September 02, 2019.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.